Elan Corporation Plc News

Elan Corporation, plc announced today that it will present at the Jefferies 2012 Global Healthcare Conference on Monday, June 4th at 9:30am Eastern Daylight Time , 2:30pm British Summer Time .

Early benefits from Express Scripts Holding's huge acquisition of Medco are being seen, such as a large windfall fromlower priced deals from manufacturers, and the lesser returns from the adoption of Medco's postage-rate strategy.

Earlier today, the trader bought a block of 1,180 October 16 calls for the ask price of $2.50 apiece.

Elan shares see notable strength following positive comments on the potential of the company's Alzheimer's drug Bapineuzumab: The FDA is signalling "they will be very reasonable about getting something to patients that has a modicum of benefit," Chairman Robert Ingram says.

WESTON, Mass. & DUBLIN-- --May 17, 2012 - Biogen Idec and Elan Corporation , plc today announced that the New England Journal of Medicine published research from the companies' global risk management program that updates the risk of TYSABRI -associated progressive multifocal leukoencephalopathy , an infrequent but serious brain infection that ... (more)

Rainbow Biosciences, the biotechnology subsidiary of Rainbow Coral Corp. , announced today that the company is currently discussing a potential joint venture with emerging biotech innovator Amarantus BioSciences .

The trailing-twelve-month operating margin at Valeant Pharmaceuticals International Inc is 24.98%. VRX's revenue for the same period is $2.75 billion.

NOKOMIS, Fla. -- -- Rainbow BioSciences, LLC, the biotech subsidiary of Rainbow Coral Corp.

NOKOMIS, Fla. & SUNNYVALE, Calif. -- -- Rainbow BioSciences, a subsidiary of Rainbow Coral Corp has executed a Letter Of Intent to advance Amarantus BioSciences, Inc.'s Parkinson's disease program, comprised of an early detection diagnostic blood test and a disease-modifying protein drug candidate.